Gaba Ron C, Elkhadragy Lobna, Boas F Edward, Chaki Sulalita, Chen Hanna H, El-Kebir Mohammed, Garcia Kelly D, Giurini Eileena F, Guzman Grace, LoBianco Francesca V, Neto Mario F, Newson Jordan L, Qazi Aisha, Regan Maureen, Rund Lauretta A, Schwind Regina M, Stewart Matthew C, Thomas Faith M, Whiteley Herbert E, Wu Jiaqi, Schook Lawrence B, Schachtschneider Kyle M
Department of Radiology, University of Illinois at Chicago, Chicago, IL, USA.
Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.
Oncotarget. 2020 Jul 14;11(28):2686-2701. doi: 10.18632/oncotarget.27647.
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. New animal models that faithfully recapitulate human HCC phenotypes are required to address unmet clinical needs and advance standard-of-care therapeutics. This study utilized the Oncopig Cancer Model to develop a translational porcine HCC model which can serve as a bridge between murine studies and human clinical practice. Reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs. Oncopig and human HCC cell lines displayed similar cell cycle lengths, alpha-fetoprotein production, arginase-1 staining, chemosusceptibility, and drug metabolizing enzyme expression. The ability of Oncopig HCC cells to consistently produce tumors was confirmed via subcutaneous (SQ) injection into immunodeficient mice and Oncopigs. Reproducible development of intrahepatic tumors in an alcohol-induced fibrotic microenvironment was achieved via engraftment of SQ tumors into fibrotic Oncopig livers. Whole-genome sequencing demontrated intrahepatic tumor tissue resembled human HCC at the genomic level. Finally, Oncopig HCC cells are amenable to gene editing for development of personalized HCC tumors. This study provides a novel, clinically-relevant porcine HCC model which holds great promise for improving HCC outcomes through testing of novel therapeutic approaches to accelerate and enhance clinical trials.
肝细胞癌(HCC)是全球癌症相关死亡的第二大主要原因。需要能够忠实地重现人类HCC表型的新动物模型,以满足未满足的临床需求并推进标准治疗方法。本研究利用Oncopig癌症模型开发了一种转化性猪HCC模型,该模型可作为小鼠研究与人类临床实践之间的桥梁。通过对15只Oncopig进行肝细胞分离和Cre重组酶暴露,证明了Oncopig HCC细胞系的可靠开发。Oncopig和人类HCC细胞系表现出相似的细胞周期长度、甲胎蛋白产生、精氨酸酶-1染色、化学敏感性和药物代谢酶表达。通过皮下(SQ)注射到免疫缺陷小鼠和Oncopig中,证实了Oncopig HCC细胞持续产生肿瘤的能力。通过将SQ肿瘤移植到纤维化的Oncopig肝脏中,在酒精诱导的纤维化微环境中实现了肝内肿瘤的可重复发展。全基因组测序表明,肝内肿瘤组织在基因组水平上类似于人类HCC。最后,Oncopig HCC细胞适合进行基因编辑,以开发个性化的HCC肿瘤。本研究提供了一种新的、与临床相关的猪HCC模型,通过测试新的治疗方法以加速和加强临床试验,有望改善HCC的治疗结果。